Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · BILL · 116th Congress · H.R. 7839 (Introduced in House) — To amend the Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012 to extend the Medicar... · Sec. 2

Sec. 2. Extension of Medicare patient IVIG access demonstration project

333 words·~2 min read·/bill/116/hr/7839/ih/section-2

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Section 101(b) of the Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012 ( 42 U.S.C. 13951 note) is amended— by striking paragraph
(1)and inserting the following: Beginning not later than one year after the date of enactment of this Act, the Secretary shall conduct the demonstration project for a period of 3 years and, subject to the availability of funds under subsection (g), the period beginning on October 1, 2017, and ending on December 31, 2022. ; and in paragraph (2)— by striking 4,000 and inserting 6,500 ; and by striking 2020 and inserting 2022 . Section 101(f) is amended— by redesignating paragraph
(2)as paragraph (3); and by inserting after paragraph
(1)the following new paragraph: Not later than one year after the date of the enactment of the Continuing Access to In-Home IVIG Act, the Secretary shall submit to Congress an updated report that contains the following: The total number of beneficiaries enrolled in the demonstration project during the updated report period. The total number of claims submitted for services during the updated report period, disaggregated by month. An analysis of the impact of the demonstration on beneficiary access to the in-home administration of intravenous immune globin, including the impact on beneficiary health and well-being. An analysis of the impact of in-home administration of intravenous immune globin on overall costs to Medicare, including the cost differential between in-home administration of intravenous immune globin and administration of intravenous immune globin in a healthcare facility. A survey of providers and enrolled beneficiaries that participated in the demonstration project that identifies barriers to accessing services, including reimbursement for items and services. Recommendations to Congress on the appropriateness of establishing a permanent bundled services payment for the in-home administration of intravenous immune globin for Medicare beneficiaries. . Section 101(h) is amended by adding at the end the following new paragraph: The term updated report period means the period beginning on October 1, 2014, and ending on September 30, 2020. .
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 2
Extension of Medicare patient IVIG access demonstration project
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.